Source: Mary Ann Liebert, Inc.
Date: December 20, 2007
Summary:
In a groundbreaking experiment published in Cloning & Stem Cells, scientists from International Stem Cell Corporation derived four unique embryonic stem cell lines that open the door for the creation of therapeutic cells that will not provoke an immune reaction in large segments of the population. The stem cell lines are “HLA-homozygous,” meaning that they have a simple genetic profile in the critical areas of the DNA that code for immune rejection. The lines could serve to create a stem cell bank as a renewable source of transplantable cells for use in cell therapy to replace damaged tissues or to treat genetic and degenerative diseases.
